UK revokes marketing authorization for Valneva's IXCHIQ chikungunya vaccine
The UK Medicines and Healthcare products Regulatory Agency has revoked the marketing authorization for Valneva's IXCHIQ chikungunya vaccine following a benefit-risk assessment by the Commission on Human Medicines. The decision caused Valneva shares to fall on Monday.
